Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma 2Leukemia, Myeloid, Acute 2Triple Negative Breast Neoplasms 1Sezary Syndrome 1Recurrence 1Multiple Myeloma 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Leukemia 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Breast Carcinoma In Situ 1Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus) 1

Interventions

talimogene laherparepvec 1poly(I).poly(c12,U) 1pasireotide 1liposomal doxorubicin 1Taxes 1Tamoxifen 1Sulindac 1Palliative Care 1Paclitaxel 1Nivolumab 1Neoadjuvant Therapy 1Metformin 1Letrozole 1Ipilimumab 1Introns 1Interferon alpha-2 1Immunohistochemistry 1Fluorescent Antibody Technique 1Flow Cytometry 1Fatty Acids, Omega-3 1Doxorubicin 1Docosahexaenoic Acids 1Cyclophosphamide 1Celecoxib 1CTLA-4 Antigen 1Biopsy 1Bexarotene 1Atorvastatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Carcinoma In Situ × Bexarotene × Clear all
NCT03323658 2023-01-10

Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled 12 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡